ReviewJournal of industrial microbiology & biotechnology2021
Genome mining for drug discovery: progress at the front end.
Review in Journal of industrial microbiology & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Discovery of Suomilide and Cyanopeptolin Analogues byJournal of natural products · 2026Article
- Predator avoidance promotes inter-bacterial symbiosis with myxobacteria in polymicrobial communities.bioRxiv : the preprint server for biology · 2026Article
- Predator avoidance promotes interbacterial symbiosis with myxobacteria in polymicrobial communities.The ISME journal · 2026Article
- A Rapid and Cost-Effective Pipeline to Identify and Capture BGCs From Bacterial Draft Genomes.Bio-protocol · 2025Article
- Recent strategies and methodological advances for microbial natural product research in the post-genomics era.Archives of microbiology · 2025Review
- Genome mining of Streptomyces bambergiensis AC-800 unravels the biosynthetic gene cluster for inhibitors of prolyl hydroxylase fibrostatins.Scientific reports · 2025Article
- Microorganisms in Macroalgae Cultivation Ecosystems: A Systematic Review and Future Prospects Based on Bibliometric Analysis.Microorganisms · 2025Review
- Enabling Access to Novel Bacterial Biosynthetic Potential From ONT Draft Genomic Data.Microbial biotechnology · 2025Article
- Decontamination of DNA sequences from a Streptomyces genome for optimal genome mining.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Amphibian skin bacteria contain a wide repertoire of genes linked to their antifungal capacities.World journal of microbiology & biotechnology · 2025Article
- Metabolomic and genomic insights into Micromonospora carbonacea subsp. caeruleus for anti-colorectal compound.Applied microbiology and biotechnology · 2025Article
- Actinomycetes - The Repertoire of Diverse Bioactive Chemical Molecules: From Structures to Antibiotics.Current topics in medicinal chemistry · 2025Review
- Streptomyces sp. from desert soil as a biofactory for antioxidants with radical scavenging and iron chelating potential.BMC microbiology · 2024Article
- The role of Streptomyces to achieve the United Nations sustainable development goals. Burning questions in searching for new compounds.Microbial biotechnology · 2024Article
- A treasure trove of 1034 actinomycete genomes.Nucleic acids research · 2024Article
- BGCFlow: systematic pangenome workflow for the analysis of biosynthetic gene clusters across large genomic datasets.Nucleic acids research · 2024Article
- Metagenomic nanopore sequencing for exploring the nature of antimicrobial metabolites of Bacillus haynesii.AMB Express · 2024Article
- Natural Products and Pharmacological Properties of Symbiotic Bacillota (Firmicutes) of Marine Macroalgae.Marine drugs · 2023Review
- Identification of the lipodepsipeptide selethramide encoded in a giant nonribosomal peptide synthetase from aProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Genetic manipulation and tools in myxobacteria for the exploitation of secondary metabolism.Engineering microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial genome mining for drug discovery and development has been accelerating in recent years, driven by technical advancements in genome sequencing, bioinformatics, metabolomics/metabologenomics, and synthetic biology. Microbial genome mining is a multistep process that starts with the sequencing of microbes that encode multiple secondary metabolites and identifying new and novel secondary metabolite biosynthetic gene clusters (BGCs) to pursue. The initial steps in the process are critical for the overall success, and they encompass the most innovative new technologies to revitalize natural product discovery. As microbial genome mining has matured in recent years, unvalidated conjectures about what microbes to pursue, how to identify legitimate secondary metabolite BGCs, and how to sequence DNA to satisfactory levels of completion have been identified. The solutions to correct the misconceptions around these topics are beginning to be implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.